Intravascular Lithotripsy: Outcomes and Trends in the Treatment of Calcified Coronary Lesions

Lately, the complexity of percutaneous coronary artery interventions (PCI) has seen an increase, mainly driven by the increasing prevalence of coronary lesion calcification, which represents a significant challenge for interventionists. Untreated calcification might result in insufficient stent expansion, a high risk factor of thrombosis and instent restenosis. 

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

Historically, several devices have been used to treat calcification, such as non-compliant high pressure balloons, cutting or scoring balloons and atherectomy. However, these methods can have limitations to effectively modify calcium. Since 2021, intravascular lithotripsy (IVL) has emerged as a promising solution, with safety and efficacy rates higher than 90%.

The aim of this study was to assess the trends and outcomes of IVL, rotational/orbital atherectomy, or both among patients undergoing PCI in Michigan, US. 

Primary end point was adverse cardiovascular events (MACE), defined as the combination of in-hospital mortality, stroke, periprocedural acute MI, coronary perforation or tamponade. Another variable was procedural success. 

Read also: Edge-to-Edge Repair for Right Ventricular Function Deterioration.

The study included 42,440 patients treated with PCI between 2021 and 2022, mean age 72, mainly men. IVL was used in 2.57%, atherectomy in 4.10%, and both in 0.57% of cases. During the study period, IVL use increased from 0.04% in 2021 to 4.28% in 2022, while the use of atherectomy dropped from 4.41% to 3.63%. The anterior descending was the most frequently treated artery both with IVL and atherectomy. 

There were no significant differences in MACE rate (4.3% vs. 5.4%; P = 0.23) or procedural success (89.4% vs. 89.1%; P = 0.88) between patients treated with IVL and those treated with atherectomy. Only 15.6% of patients treated with IVL in the contemporary practice were similar to the population included in the relevant IVL the clinical trials. Among these patients (n = 169), MACE (0.0%) and procedural success rates (94.7%) were comparable to the outcomes reported by the relevant IVL studies. 

Conclusion

Since its approval, the use of IVL has seen a significant increase and is, at present, the go-to technique to modify coronary plaque. Both IVL and atherectomy have been associated to similar rates and have generally few complications, and high procedural success rates. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Contemporary Trends and Outcomes of Intravascular Lithotripsy in Percutaneous Coronary Intervention Insights From BMC2.

Reference: Devraj Sukul, MD, MSC et al J Am Coll Cardiol Intv 2024.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...